Telix shares extend gains amid 'evolving' leadership changes

An 'internal reorganisation' is underway at Telix.

| More on:
Health professional looking at a laptop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Telix Pharmaceuticals Ltd (ASX: TLX) shares are drifting higher on Tuesday, extending gains to 98% for the year to date.

Shares in the biopharmaceutical company are swapping hands less than 1% higher at $19.90 apiece at the time of publication.

Whilst there's been nothing market-sensitive from the company today, it did announce a number of executive changes as part of an "internal reorganisation".

Let's dive in.

Created with Highcharts 11.4.3Telix Pharmaceuticals PriceZoom1M3M6MYTD1Y5Y10YALL1 Aug 202327 Aug 2024Zoom ▾Sep '23Nov '23Jan '24Mar '24May '24Jul '24Sep '23Sep '23Jan '24Jan '24May '24May '24www.fool.com.au

New leadership announced at Telix

Telix shares are relatively flat today, but the business announced several new leadership changes as part of a broader reorganisation, as it "reflec[ts] its focus".

This reorganisation is designed to "align" operations across its four business units and sees new executives at several posts.

There are a few 3 and 4-letter acronyms to come, so bear with me.

Richard Valeix, now the former chief commercial officer (CCO), is now chief executive officer (CEO) of Telix Therapeutics.

He will spearhead the commercialisation of Telix's therapeutic pipeline, which includes candidates for prostate, kidney, and brain cancer.

Secondly, Kevin Richardson, previously CEO of Telix's Americas division, takes on the role of CEO of Telix Precision Medicine. He will lead the development of diagnostic tools and oversee operations in North America.

Meanwhile, Raphael Ortiz has been appointed CEO of Telix International, responsible for commercial activities across Europe, the Middle East, Africa (EMEA), Asia Pacific (APAC), and Latin America (LatAm).

Telix's Managing Director and the overall group CEO, Dr Christian Behrenbruch, emphasised the importance of these changes:

Telix is at an inflection point: momentum in our therapeutics business is growing, with prostate, kidney and brain cancer therapeutic candidates currently in, or advancing to, pivotal clinical trials. Precision medicine is our global commercialisation engine, to bring personalised, theranostic solutions to market and is underpinned by a growing manufacturing footprint that enables enhanced control over the supply chain.

Telix is evolving, and the revised business model reflects our differentiated position, harnessing the power of targeted radiation at every step of the patient journey.

FY24 earnings a mixed outcome for Telix shares

Aside from the management changes, the biopharma and radiopharmaceutical company also posted its FY24 earnings last week.

Telix shares dipped after the release of the company's half-year results, despite a strong period of growth from the business.

It reported a 65% increase in revenue, reaching $364 million.

Growth was underscored by strong sales of its prostate cancer imaging agent, Illuccix, in the US.

Net profit for the half-year was $30 million, a significant turnaround from the $14 million loss in the prior year.

After a brief sell off, shares have regained momentum. Telix shares first dipped to $19.18 in the days following. But they are now drifting back to their 3-month closing highs of $20.31.

Telix shares snapshot

Telix shares have performed tremendously well over the past 12 months. The stock is up more than 85% during that time, lifting around 3.5% in the past month alone.

Owning Telix shares provided a 75% advantage over the past year.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »